AZN AstraZeneca PLC ADR

$80.97

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 8/22/2025

About AstraZeneca PLC ADR

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Website: https://www.astrazeneca.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
901832
Address
1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE, GB
Valuation
Market Cap
$209.55B
P/E Ratio
30.04
PEG Ratio
0.96
Price to Book
6.19
Performance
EPS
$2.25
Dividend Yield
2.29%
Profit Margin
13.00%
ROE
17.60%
Technicals
50D MA
$73.24
200D MA
$73.97
52W High
$86.46
52W Low
$61.24
Fundamentals
Shares Outstanding
3B
Target Price
$84.79
Beta
0.25

AZN EPS Estimates vs Actual

Estimated
Actual

AZN News & Sentiment

Aug 22, 2025 • Zacks Commentary NEUTRAL
Short-Term Pain, Long-Term Gain? 4 Quantum Stocks to Watch
IonQ, D-Wave, Rigetti and QUBT report steep Q2 losses but strengthen cash positions with major fundraising to fuel quantum growth.
Aug 22, 2025 • Benzinga NEUTRAL
UK Drug Pricing Talks Collapse, Drugmakers Reject Offer Citing 'Uncompetitive' System - AstraZeneca ( NASDAQ:AZN ) , Novartis ( NYSE:NVS )
UK drug rebate system takes back 23% of sales above budget cap, nearly triple EU levels. The government's plan to double the share of medicine spending in GDP has been delayed until 2029. See the 6X seasonal strategy set to target this fall's biggest opportunities. Details here →
Aug 22, 2025 • Zacks Commentary NEUTRAL
ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth
AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.
Aug 22, 2025 • Benzinga NEUTRAL
J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs - AstraZeneca ( NASDAQ:AZN ) , Biogen ( NASDAQ:BIIB )
Johnson & Johnson JNJ is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration. J&J announced its investment on Thursday, as reported by Reuters.
Aug 20, 2025 • Benzinga NEUTRAL
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates - Ascentage Pharma Group ( NASDAQ:AAPG )
Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million ( RMB217.4 million ) , primarily attributable to the expansion of NRDL coverage
Aug 20, 2025 • GlobeNewswire NEUTRAL
Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates
ROCKVILLE, Md. and SUZHOU, China, Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma Group International ( Ascentage Pharma ) ( NASDAQ: AAPG. HKEX: 6855 ) ( referred hereinto as "Ascentage Pharma," the "Company," "we," "us" or "our" ) , a global, commercial stage, integrated biopharmaceutical ...
Sentiment Snapshot

Average Sentiment Score:

0.084
50 articles with scored sentiment

Overall Sentiment:

Neutral

AZN Reported Earnings

Apr 23, 2025
Mar 31, 2025 (Pre market)
-0.18 Surprise
  • Reported EPS: $0.93
  • Estimate: $1.12
  • Whisper:
  • Surprise %: -16.3%
Feb 06, 2025
Dec 31, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $1.04
  • Estimate: $1.04
  • Whisper:
  • Surprise %: 0.8%
Nov 12, 2024
Sep 30, 2024 (Pre market)
-0.58 Surprise
  • Reported EPS: $0.46
  • Estimate: $1.04
  • Whisper:
  • Surprise %: -56.0%
Jul 25, 2024
Jun 30, 2024 (Pre market)
-0.21 Surprise
  • Reported EPS: $0.99
  • Estimate: $1.20
  • Whisper:
  • Surprise %: -17.5%
Apr 25, 2024
Mar 31, 2024 (Pre market)
-0.19 Surprise
  • Reported EPS: $1.03
  • Estimate: $1.22
  • Whisper:
  • Surprise %: -15.6%
Feb 08, 2024
Dec 31, 2023 (Pre market)
-0.06 Surprise
  • Reported EPS: $0.73
  • Estimate: $0.79
  • Whisper:
  • Surprise %: -7.6%
Nov 09, 2023
Sep 30, 2023 (Pre market)
0.02 Surprise
  • Reported EPS: $0.87
  • Estimate: $0.85
  • Whisper:
  • Surprise %: 2.4%
Jul 28, 2023
Jun 30, 2023 (Pre market)
0.13 Surprise
  • Reported EPS: $1.08
  • Estimate: $0.95
  • Whisper:
  • Surprise %: 13.7%
Apr 27, 2023
Mar 31, 2023 (Pre market)
-0.11 Surprise
  • Reported EPS: $0.96
  • Estimate: $1.07
  • Whisper:
  • Surprise %: -10.3%

Financials